MedTrace Logo

CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients

NCT03902197 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-04-08

No results posted yet for this study

Summary

This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T) in refractory/relapsed CD19+ B-ALL leukemia patients who have no available curative treatment options, have a limited prognosis with currently available treatments, and were previously treated with a B cell directed cell therapy.

Conditions

Interventions

BIOLOGICAL

CD19 hsCAR-T

CD19 hsCAR-T will be administered by I.V. infusion

Sponsors & Collaborators

  • Beijing Children's Hospital

    collaborator OTHER

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Zhiguo Chen, PhD · Xuanwu Hospital, Beijing

  • Huyong Zheng, MD, PhD · Beijing Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2021-12-31
Completion
2023-12-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03902197 on ClinicalTrials.gov